Work

Lefamulin or moxifloxacin for community-acquired pneumonia: balancing innovation, safety, and evidence

Year: 2025

Type: article

Abstract: The recent approval of lefamulin presents an alternative to fluoroquinolones for community-acquired pneumonia. In recent trials, lefamulin matched moxifloxacin in early clinical response and safety, with a favorable activity spectrum including atypical pathogens. However, fluoroquinolones remain entrenched due to cost, clinician familiarity, and broad guidelines. This letter examines current evidence comparing the two, highlights potential niches for lefamulin, and calls for more trials to guide adoption in diverse healthcare settings.

Source: Annals of Medicine and Surgery

DOI: 10.1097/ms9.0000000000004342

Authors: Saad Arsalan Wasti, Areesha Wasti, Muhammad Usman Iqbal, Naseeb Danaf

Institutions: King Edward Medical University, Lebanese University

Language: English

Topic: Pneumonia and Respiratory Infections

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,850